secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2023-07-28T23:59:59+00:00
Accession:  0001935979-23-000046
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA refuses troriluzole NDA for SCA; BHV-7000 EEG data positive
---------------------------------------------------------------

- FDA refused to file troriluzole NDA for SCA because primary endpoint not met; company may request Type A meeting within 30 days.
- BHV-7000: preliminary EEG data shows target engagement with no somnolence/fatigue; pivotal studies in epilepsy/bipolar disorder planned for 2H2023.
- BHV-8000 Phase 1: three dose cohorts dosed, well tolerated, achieved projected therapeutic concentrations; Phase 2 in Parkinson's planned for 2024.
- BHV-1300 bispecific IgG degrader advancing to IND in 2H2023; competitive safety and manufacturing profile.
- Once-daily extended-release formulation for BHV-7000 confirmed for Phase 2/3 programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597923000046/0001935979-23-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597923000046/bhvn-20230727.htm
  HTML page:      https://secwatch.observer/filing/0001935979-23-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer